Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Molecules ; 27(18)2022 Sep 10.
Article de Anglais | MEDLINE | ID: mdl-36144626

RÉSUMÉ

Previous investigations of the Leishmania infantum eIF4A-like protein (LieIF4A) as a potential drug target delivered cholestanol derivatives inhibitors. Here, we investigated the mode of action of cholesterol derivatives as a novel scaffold structure of LieIF4A inhibitors on the RNA-dependent ATPase activity of LieIF4A and its mammalian ortholog (eIF4AI). We compared their biochemical effects on RNA-dependent ATPase activities of both proteins and investigated if rocaglamide, a known inhibitor of eIF4A, could affect LieIF4A as well. Kinetic measurements were conducted at different concentrations of ATP, of the compound and in the presence of saturating whole yeast RNA concentrations. Kinetic analyses showed different ATP binding affinities for the two enzymes as well as different sensitivities to 7-α-aminocholesterol and rocaglamide. The 7-α-aminocholesterol inhibited LieIF4A with a higher binding affinity relative to cholestanol analogs. Cholesterol, another tested sterol, had no effect on the ATPase activity of LieIF4A or eIF4AI. The 7-α-aminocholesterol demonstrated an anti-Leishmania activity on L. infantum promastigotes. Additionally, docking simulations explained the importance of the double bond between C5 and C6 in 7-α-aminocholesterol and the amino group in the C7 position. In conclusion, Leishmania and mammalian eIF4A proteins appeared to interact differently with effectors, thus making LieIF4A a potential drug against leishmaniases.


Sujet(s)
Facteur-4A d'initiation eucaryote , Leishmania infantum , Adenosine triphosphatases/métabolisme , Adénosine triphosphate/métabolisme , Animaux , Cholestanols/métabolisme , Cholestérol/métabolisme , Facteur-4A d'initiation eucaryote/composition chimique , Facteur-4A d'initiation eucaryote/génétique , Facteur-4A d'initiation eucaryote/métabolisme , Mammifères/métabolisme , Souris , Protéines/métabolisme , ARN/métabolisme , Stérols/métabolisme , Stérols/pharmacologie
2.
PLoS Negl Trop Dis ; 12(1): e0006160, 2018 01.
Article de Anglais | MEDLINE | ID: mdl-29346371

RÉSUMÉ

Leishmaniases are neglected parasitic diseases in spite of the major burden they inflict on public health. The identification of novel drugs and targets constitutes a research priority. For that purpose we used Leishmania infantum initiation factor 4A (LieIF), an essential translation initiation factor that belongs to the DEAD-box proteins family, as a potential drug target. We modeled its structure and identified two potential binding sites. A virtual screening of a diverse chemical library was performed for both sites. The results were analyzed with an in-house version of the Self-Organizing Maps algorithm combined with multiple filters, which led to the selection of 305 molecules. Effects of these molecules on the ATPase activity of LieIF permitted the identification of a promising hit (208) having a half maximal inhibitory concentration (IC50) of 150 ± 15 µM for 1 µM of protein. Ten chemical analogues of compound 208 were identified and two additional inhibitors were selected (20 and 48). These compounds inhibited the mammalian eIF4I with IC50 values within the same range. All three hits affected the viability of the extra-cellular form of L. infantum parasites with IC50 values at low micromolar concentrations. These molecules showed non-significant toxicity toward THP-1 macrophages. Furthermore, their anti-leishmanial activity was validated with experimental assays on L. infantum intramacrophage amastigotes showing IC50 values lower than 4.2 µM. Selected compounds exhibited selectivity indexes between 19 to 38, which reflects their potential as promising anti-Leishmania molecules.


Sujet(s)
Antiprotozoaires/isolement et purification , Antiprotozoaires/pharmacologie , Évaluation préclinique de médicament/méthodes , Facteur-4A d'initiation eucaryote/antagonistes et inhibiteurs , Leishmania infantum/effets des médicaments et des substances chimiques , Leishmania infantum/enzymologie , Adenosine triphosphatases/analyse , Adenosine triphosphatases/antagonistes et inhibiteurs , Sites de fixation , Facteur-4A d'initiation eucaryote/composition chimique , Concentration inhibitrice 50 , Modèles moléculaires , Simulation de docking moléculaire , Tests de sensibilité parasitaire
3.
Article de Anglais | MEDLINE | ID: mdl-27807464

RÉSUMÉ

We report the chemical composition and anti-Leishmania and antioxidant activity of Artemisia campestris L. and Artemisia herba-alba Asso. essential oils (EOs). Our results showed that these extracts exhibit different antioxidant activities according to the used assay. The radical scavenging effects determined by DPPH assay were of IC50 = 3.3 mg/mL and IC50 = 9.1 mg/mL for Artemisia campestris and Artemisia herba-alba essential oils, respectively. However, antioxidant effects of both essential oils, determined by ferric-reducing antioxidant power (FRAP) assay, were in the same range (2.3 and 2.97 mg eq EDTA/g EO, resp.), while the Artemisia herba-alba essential oil showed highest chelating activity of Fe2+ ions (27.48 mM Fe2+). Interestingly, we showed that both EOs possess dose-dependent activity against Leishmania infantum promastigotes with IC50 values of 68 µg/mL and 44 µg/mL for A. herba-alba and A. campestris, respectively. We reported, for the first time, that antileishmanial activity of both EOs was mediated by cell apoptosis induction and cell cycle arrest at the sub-G0/G1 phase. All our results showed that EOs from A. herba-alba and A. campestris plants are promising candidates as anti-Leishmania medicinal products.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...